Device type · JBF
Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
JBF
Hematology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening
- Product code
- JBF
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7360
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for JBF
Latest FDA decisions
- FINDER G6PD510(k)
K201049 · Decided Sep 14, 2022 · 876 days after receipt
Device type: Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening (JBF) · Laboratory Medicine & Pathology
- BinaxNOW G6PD Test510(k)
K161364 · Decided Jun 17, 2016 · 31 days after receipt
Device type: Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening (JBF) · Laboratory Medicine & Pathology
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2487-2015 · Started May 19, 2015 · Posted by FDA Aug 31, 2015
Reason given: A reduction in the reconstituted stability has been identified. Clinicians may notice a drop in recovery of the control after reconstitution, which could result in an out of specification result prior to the current reconstitution claim of 7 days. For this reason we suggest discontinuing use of the control set.
Cause as FDA categorized it: Nonconforming Material/Component
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.